This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Resumen de acción MGTA
Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Competidores de Magenta Therapeutics, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.70 |
| 52 Week High | US$2.07 |
| 52 Week Low | US$0.32 |
| Beta | 2.11 |
| 1 Month Change | -13.09% |
| 3 Month Change | -0.057% |
| 1 Year Change | -62.79% |
| 3 Year Change | -91.00% |
| 5 Year Change | -94.08% |
| Change since IPO | -95.18% |
Noticias y actualizaciones recientes
Recent updates
Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?
Dec 10
Magenta Therapeutics downgraded to neutral at Goldman Sachs on clarity over candidate
Aug 25Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?
Jul 13Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation
Apr 12Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation
Dec 16Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans
Aug 26Magenta Therapeutics (MGTA) EHA Investor Presentations - Slideshow
Jun 18We're Not Very Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Rate
May 09Magenta Therapeutics EPS beats by $0.04
May 06What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?
Mar 17Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans
Jan 23
Magenta Therapeutics announces expected 2021 highlights milestones
Jan 11What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?
Dec 01Rentabilidad de los accionistas
| MGTA | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -6.0% | -2.5% | -3.2% |
| 1Y | -62.8% | -3.7% | 19.3% |
Rentabilidad vs. Industria: MGTA underperformed the US Biotechs industry which returned 3.8% over the past year.
Rentabilidad vs. Mercado: MGTA underperformed the US Market which returned 7.5% over the past year.
Volatilidad de los precios
| MGTA volatility | |
|---|---|
| MGTA Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: MGTA has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: MGTA's weekly volatility has decreased from 15% to 6% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2015 | 67 | n/a | www.magentatx.com |
Resumen de fundamentos de Magenta Therapeutics, Inc.
| Estadísticas fundamentales de MGTA | |
|---|---|
| Capitalización bursátil | US$42.24m |
| Beneficios(TTM) | -US$68.69m |
| Ingresos (TTM) | n/a |
0.0x
Ratio precio-ventas (PS)-0.6x
Ratio precio-beneficio (PE)¿Está MGTA sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de MGTA | |
|---|---|
| Ingresos | US$0 |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$0 |
| Otros gastos | US$68.70m |
| Beneficios | -US$68.69m |
Últimos beneficios comunicados
Jun 30, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.14 |
| Margen bruto | 0.00% |
| Margen de beneficio neto | 0.00% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado MGTA a largo plazo?
Ver rendimiento histórico y comparativa